Alterity Therapeutics Ltd
ATHE5.210USD
+0.200+3.99%
Horarios del mercado （ET）Cotizaciones retrasadas 15 min
46.20MCap. mercado
--P/E TTM
Más Datos de Alterity Therapeutics Ltd Compañía
Alterity Therapeutics Limited is an Australia-based clinical-stage biotechnology company. The Company is focused on developing disease modifying treatments for neurodegenerative diseases. The Company's lead asset, ATH434, is to treat various Parkinsonian disorders. ATH434 is an oral agent designed to inhibit the aggregation of pathological proteins implicated in neurodegeneration. It has the potential to treat Parkinson's disease, as well as various Parkinsonian disorders, such as Multiple System Atrophy (MSA). The Company also has a drug discovery platform generating patentable chemical compounds to intercede in disease processes. ATH434 has been granted Orphan designation for the treatment of MSA. The Phase II clinical trial is a randomized, double-blind, placebo-controlled investigation of ATH434 in patients with early-stage MSA.
Información de la empresa
Símbolo de cotizaciónATHE
Nombre de la empresaAlterity Therapeutics Ltd
Fecha de salida a bolsaMar 28, 2000
Director ejecutivoDr. David A. Stamler, M.D.
Número de empleados10
Tipo de seguridadDepository Receipt
Fin del año fiscalMar 28
DirecciónL 3 460 Bourke St
CiudadMELBOURNE
Bolsa de valoresNASDAQ Capital Market Consolidated
PaísAustralia
Código postal3000
Teléfono61393494906
Sitio Webhttps://alteritytherapeutics.com/
Símbolo de cotizaciónATHE
Fecha de salida a bolsaMar 28, 2000
Director ejecutivoDr. David A. Stamler, M.D.
Ejecutivos de la empresa
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Ms. Abby Macnish Niven
Ms. Abby Macnish Niven
Chief Financial Officer, Company Secretary
Chief Financial Officer, Company Secretary
--
--
Mr. Lawrence B. Gozlan
Mr. Lawrence B. Gozlan
Non-Executive Director
Non-Executive Director
--
--
Mr. Peter Ashley Marks
Mr. Peter Ashley Marks
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Mr. Brian Derek Meltzer
Mr. Brian Derek Meltzer
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Ms. Hannah Howlett
Ms. Hannah Howlett
Investor Relations
Investor Relations
--
--
Mr. Geoffrey Paul Kempler
Mr. Geoffrey Paul Kempler
Non-Executive Chairman of the Board
Non-Executive Chairman of the Board
--
--
Dr. David A. Stamler, M.D.
Dr. David A. Stamler, M.D.
Chief Executive Officer
Chief Executive Officer
--
--
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Ms. Abby Macnish Niven
Ms. Abby Macnish Niven
Chief Financial Officer, Company Secretary
Chief Financial Officer, Company Secretary
--
--
Mr. Lawrence B. Gozlan
Mr. Lawrence B. Gozlan
Non-Executive Director
Non-Executive Director
--
--
Mr. Peter Ashley Marks
Mr. Peter Ashley Marks
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Mr. Brian Derek Meltzer
Mr. Brian Derek Meltzer
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Ms. Hannah Howlett
Ms. Hannah Howlett
Investor Relations
Investor Relations
--
--
Mr. Geoffrey Paul Kempler
Mr. Geoffrey Paul Kempler
Non-Executive Chairman of the Board
Non-Executive Chairman of the Board
--
--
Desglose de ingresos
Sin datos
Sin datos
Por negocio
Por región
Sin datos
Estadísticas de accionistas
Actualizado: dom., 20 de jul
Actualizado: dom., 20 de jul
Accionistas
Tipos de accionistas
Accionistas
Accionistas
Proporción
Point72 Asset Management, L.P.
0.86%
Morgan Stanley & Co. LLC
0.28%
Greenleaf Trust
0.11%
UBS Financial Services, Inc.
0.08%
BNP Paribas Securities Corp. North America
0.06%
Other
98.60%
Accionistas
Accionistas
Proporción
Point72 Asset Management, L.P.
0.86%
Morgan Stanley & Co. LLC
0.28%
Greenleaf Trust
0.11%
UBS Financial Services, Inc.
0.08%
BNP Paribas Securities Corp. North America
0.06%
Other
98.60%
Tipos de accionistas
Accionistas
Proporción
Hedge Fund
0.86%
Research Firm
0.35%
Bank and Trust
0.11%
Investment Advisor
0.09%
Private Equity
0.04%
Other
98.56%
Participación institucional
Actualizado: mar., 1 de jul
Actualizado: mar., 1 de jul
Periodo del informe
Número de instituciones
Acciones mantenidas
Proporción
Cambio
2025Q2
25
222.41K
1.45%
+22.59K
2025Q1
25
242.89K
1.60%
+14.64K
2024Q4
25
125.35K
1.13%
-75.38K
2024Q3
25
113.89K
1.28%
-62.37K
2024Q2
24
79.19K
0.91%
-96.76K
2024Q1
24
95.17K
1.09%
-51.08K
2023Q4
23
88.25K
1.89%
-31.21K
2023Q3
26
59.08K
1.45%
-63.37K
2023Q2
27
58.44K
1.44%
-90.15K
2023Q1
26
93.79K
2.31%
-17.38K
Ver más
Actividad de los accionistas
Nombre
Acciones mantenidas
Proporción
Cambio
Cambio %
Fecha
Point72 Asset Management, L.P.
131.43K
0.86%
+98.80K
+302.83%
Mar 31, 2025
Morgan Stanley & Co. LLC
43.63K
0.29%
-700.00
-1.58%
Mar 31, 2025
UBS Financial Services, Inc.
13.00K
0.09%
+12.62K
+3286.46%
Mar 31, 2025
BNP Paribas Securities Corp. North America
9.75K
0.06%
+962.00
+10.94%
Mar 31, 2025
Twin Lakes Capital
5.92K
0.04%
--
--
Mar 31, 2025
Geode Capital Management, L.L.C.
1.16K
0.01%
--
--
May 31, 2025
Osaic Holdings, Inc.
181.00
0%
--
--
Mar 31, 2025
Rhumbline Advisers Ltd. Partnership
130.00
0%
+130.00
--
Mar 31, 2025
55IP
53.00
0%
+53.00
--
Mar 31, 2025
Ver más
ETFs relacionados
Nombre
Proporción
Sin datos
Dividendos
Un total de
0.00
USD se ha distribuido en dividendos durante los últimos 5 años.
Fecha
Dividendos
Fecha de registro
Fecha de pago
Fecha ex-dividendo
Sin datos
División de acciones
Fecha
Tipo
Relación
Dec 30, 2022
Merger
10<1
Dec 30, 2022
Merger
10<1
Dec 30, 2022
Merger
10<1
Dec 30, 2022
Merger
10<1
Fecha
Tipo
Relación
Dec 30, 2022
Merger
10<1
Dec 30, 2022
Merger
10<1
Dec 30, 2022
Merger
10<1
Dec 30, 2022
Merger
10<1
